Get the app
US › Healthcare

C4 Therapeutics Inc (CCCC)

US · Healthcare · Biotechnology

$3.42-1.01%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$6.6M
Revenue YoY
+2.8%
Net profit
$-23.6M
EPS
$-0.18
EPS estimate
$-0.23
Net margin
-355.9%

EPS came in at -0.18 against a street estimate of -0.23 — a beat of 21.7%.

Key statistics

Market cap
$431.8M
Forward P/E
0.0
P/B
1.75
Book value
$2.01
EPS (TTM)
$-0.91
52-week high
$5.17
52-week low
$1.69
50-day MA
$3.84
200-day MA
$3.06
Beta
2.94

Analyst view

Analysts rate C4 Therapeutics Inc a buy (4 buy, 4 hold, 0 sell out of 8) with an average price target of $13.33.

Shareholding

Insiders
0.83%
Institutions
102.75%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts7.37%
RA Capital Management, LLC6.50%
Lynx1 Capital Management, LP5.96%
Squadron Capital Management LLC5.85%
Bain Capital Life Sciences Investors, LLC5.83%
Citadel Advisors Llc3.40%
Vanguard Capital Management, LLC3.14%
Wasatch Advisors LP2.86%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for C4 Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.